For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Ametek Inc. (AME) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score -6 (−100…+100 Quality+Value blend) · Quality 72 · Value -70 · Sentiment 37 (timing only, not weighted) · Composite fair value $137.37 vs $254.79 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Ametek Inc.
AME NYSEAmetek Inc. is a global manufacturer of advanced electronic instruments and electromechanical devices serving a wide range of industrial and technology-driven markets. The company operates through two primary segments: Electronic Instruments, which provides analytical, test, and measurement instrumentation for sectors such as aerospace, energy, medical, industrial, power, and research; and Electromechanical, which supplies automation and precision motion control solutions, thermal management systems, specialty metals, and highly engineered electrical interconnects and medical components. Ametek Inc. focuses on differentiated, application-specific technologies that support customers in complex and demanding environments, from process control and power generation to medical diagnostics and aerospace systems. Headquartered in Berwyn, Pennsylvania and founded in 1930, Ametek Inc. plays a significant role in the industrials sector by providing mission-critical components and instruments that are embedded in customers’ equipment, production processes, and infrastructure worldwide.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.40
Total Equity: $10.63B
Shares: 231,259,000
Total Debt: $2.28B
Cash: $457.95M
EBITDA: $2.33B
Total Debt: $2.28B
Cash: $457.95M
Revenue: $7.40B
Revenue: $7.40B
Revenue: $7.40B
Total Equity: $10.63B
Tax Rate: 17.7%
Equity: $10.63B
Total Debt: $2.28B
Cash: $457.95M
Current Liabilities: $2.84B
Long-Term Debt: $1.07B
Total Debt: $2.28B
Total Equity: $10.63B
Shares: 231,259,000
Shares: 231,259,000
CapEx: -$130.25M
Shares: 231,259,000
Stock Price: $254.79
Net Income: $1.48B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 14, 2026 6:53pm (9d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $6.2B | $6.6B | $6.9B | $7.4B |
| Cost of Revenue | $3.6B | $4.0B | $4.2B | $4.5B | $4.7B |
| Gross Profit | — | $2.1B | $2.4B | $2.5B | $2.7B |
| Operating Expenses | $603.9M | $644.6M | $677.0M | $696.9M | $757.1M |
| Operating Income | $1.3B | $1.5B | $1.7B | $1.8B | $1.9B |
| Net Income | $990.1M | $1.2B | $1.3B | $1.4B | $1.5B |
| EBITDA | $1.6B | $1.8B | $2.0B | $2.2B | $2.3B |
| EPS | $4.29 | $5.04 | $5.70 | $5.95 | $6.42 |
| EPS (Diluted) | $4.25 | $5.01 | $5.67 | $5.93 | $6.40 |
Balance Sheet (Annual)
Last updated: Aug 11, 2026 12:49pm (12d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $346.8M | $345.4M | $409.8M | $374.0M | $458.0M |
| Total Current Assets | $2.1B | $2.5B | $2.8B | $2.6B | $3.0B |
| Total Assets | $11.9B | $12.4B | $15.0B | $14.6B | $16.1B |
| Current Liabilities | $1.6B | $1.6B | $2.9B | $2.1B | $2.8B |
| Long-Term Debt | $2.2B | $2.2B | $1.9B | $1.4B | $1.1B |
| Total Liabilities | $5.0B | $5.0B | $6.3B | $5.0B | $5.4B |
| Total Equity | $6.9B | $7.5B | $8.7B | $9.7B | $10.6B |
| Retained Earnings | $7.9B | $8.9B | $9.9B | $11.1B | $12.3B |
Cash Flow (Annual)
Last updated: Aug 14, 2026 6:53pm (9d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.2B | $1.1B | $1.7B | $1.8B | $1.8B |
| Capital Expenditure | -$110.7M | -$139.0M | -$136.2M | -$127.1M | -$130.2M |
| Free Cash Flow | $1.0B | $1.0B | $1.6B | $1.7B | $1.7B |
| Acquisitions (net) | -$2.0B | -$429.7M | -$2.2B | -$117.5M | -$933.2M |
| Net Debt Issued / (Repaid) | -$59.7M | $0 | $0 | -$300.0M | -$514.9M |
| Dividends Paid | -$184.6M | -$202.2M | -$230.3M | -$258.8M | -$285.3M |
| Stock Buybacks | -$14.7M | -$332.8M | -$7.8M | -$212.0M | -$434.0M |
| Net Change in Cash | -$866.1M | -$1.4M | $64.4M | -$35.8M | $84.0M |
Growth Trends (YoY %)
Last updated: Aug 14, 2026 6:53pm (9d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | +7.3% | +5.2% | +6.6% |
| Gross Profit Growth | — | +11.1% | +3.9% | +7.7% |
| Operating Income Growth | +14.7% | +13.8% | +4.2% | +7.3% |
| Net Income Growth | +17.1% | +13.3% | +4.8% | +7.6% |
| EBITDA Growth | +13.7% | +12.4% | +5.7% | +7.9% |
Dividend History (Last 20)
Last updated: Aug 11, 2026 12:49pm (12d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-15 | $0.34 | — | — | — |
| 2026-03-16 | $0.34 | — | — | — |
| 2025-12-05 | $0.31 | — | — | — |
| 2025-09-15 | $0.31 | — | — | — |
| 2025-06-13 | $0.31 | — | — | — |
| 2025-03-14 | $0.31 | — | — | — |
| 2024-12-06 | $0.28 | — | — | — |
| 2024-09-16 | $0.28 | — | — | — |
| 2024-06-14 | $0.28 | — | — | — |
| 2024-03-07 | $0.28 | — | — | — |
| 2023-12-07 | $0.25 | — | — | — |
| 2023-09-13 | $0.25 | — | — | — |
| 2023-06-09 | $0.25 | — | — | — |
| 2023-03-09 | $0.25 | — | — | — |
| 2022-12-06 | $0.22 | — | — | — |
| 2022-09-13 | $0.22 | — | — | — |
| 2022-06-09 | $0.22 | — | — | — |
| 2022-03-09 | $0.22 | — | — | — |
| 2021-12-07 | $0.20 | — | — | — |
| 2021-09-13 | $0.20 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-22 02:07Even the bull case prices 56% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 67%.
| Case | Growth | Margin | Fair value | vs price ($254.79) |
|---|---|---|---|---|
| Bull — recovery | +15% | 23.1% | $111.18 | -56% |
| Base — stabilizes | +10% | 20.0% | $83.83 | -67% |
| Bear — keeps slipping | +5% | 17.0% | $61.96 | -76% |
| Stress — last quarter repeats | +11% | 19.8% | $84.26 | -67% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-15AI infrastructure buildout is a direct demand pull for AMETEK's thermal management, engineered interconnects, precision motion and electronic test content used in semiconductor, power-electronics and data-center-adjacent manufacturing — a volume tailwind in an industry otherwise growing ~3.6%.
The information-processing layer of instrumentation — analysis software, workflow, interpretation — is the part AI commoditizes fastest, so differentiation migrates back toward hardware physics while software-based price premiums on some instrument lines erode.
Whether AMETEK keeps monetizing intelligence as instrument content (higher ASPs, attached analytics) rather than losing it to open AI toolchains; watch organic growth and gross margin in Electronic Instruments versus Electromechanical over several quarters.
Qualified sensor and materials know-how, calibration traceability, aerospace/medical certifications, decades-long design-in positions on flying and implanted platforms, and a distributed installed base of instruments in labs and plants.
AI Lens thesis
AI reaches AMETEK through three narrow channels rather than the core: it can automate the analysis and interface layer sitting atop instruments, which is a modest pricing risk on the software-differentiated end of Electronic Instruments; it lowers the engineering and SG&A cost of running ~30-plus decentralized niche businesses, which in a 36% gross margin / 25.8% operating margin structure with $1.67B FCF converts into incremental margin and faster acquisition integration; and it raises demand for the physical enablers of compute — thermal management, interconnects, motion and test equipment for semiconductor and power electronics. The customer need (measure, move, cool, connect with certified precision) is physics, not cognition, so the solution persists; the monetized unit is a shipped device, not a seat or a billable hour, which insulates revenue from the seat-compression dynamic hitting software and services. The main way this goes wrong is competitive: cheap AI-assisted design plus commodity compute lets focused entrants replicate mid-tier instrument functionality, compressing the niche pricing power that justifies AMETEK's premium roll-up economics.
What the market may be underestimating
Upside AMETEK is an under-labeled AI-capex supplier: thermal management, specialty interconnect and precision motion content into semiconductor and power-electronics manufacturing can grow faster than the mature industrial average without the company being narrated as an AI name.
Downside The roll-up engine depends on paying reasonable multiples for niche leaders whose moat is partly software-defined; if AI erodes the defensibility of those targets, AMETEK could keep acquiring at premium prices into assets whose pricing power is quietly decaying.
Outcome range spread 35
Growth Outlook
Analyzed 2026-08-17 16:31The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw numbers first: AMETEK is doing $2.04B/quarter with 20% net margins, up from $1.71B two years ago — that's roughly 9% YoY revenue growth in the most recent quarter (2Q26 vs 2Q25: $2.04B vs $1.78B = 14.6% actually, better than the 6.6% "recent" figure the momentum model shows, which appears to be using stale comps). Full-year 2025 hit $7.40B rev / $1.48B NI, and if I annualize the last two quarters ($3.97B H1'26), the run-rate is roughly $7.9-8.0B for 2026, implying ~7-8% growth with margins holding at 20%. That's a genuinely healthy trajectory — not spectacular, but the deceleration narrative in the secondary signals looks wrong: sequential quarterly revenue has stepped up cleanly ($1.71→1.73→1.76→1.78→1.89→2.00→1.93→2.04B). Balance sheet is pristine: $2.28B debt against $10.63B equity and $1.67B FCF, so debt/FCF is ~1.4x. Nothing to worry about here.
Where I part ways with the synthesis: a $141 composite fair value on a business generating $1.67B FCF ($7.28/share on 220M shares roughly) growing high-single-digits with 25%+ ROIC implies a ~19x FCF multiple, which is too punitive for a defense/aerospace-levered industrial compounder with this margin profile. Peers like Roper, Fortive, TDG trade 28-35x FCF. The narrative model's read that "35-40% of valuation is story" overstates it — at 35x FCF ($254 price), you're paying a quality premium versus the S&P at ~25x, not a bubble multiple. The market forces model's "fairly valued at premium multiple" is closer to right than the synthesis's -35% overvalued call. The ROIC of 12.6% is the one number that gives me pause — it's good but not the 15%+ the pre-flight thesis assumes, and it's the return on the acquisitive capital base that justifies the roll-up premium.
The contrarian case worth taking seriously: aerospace/defense is 30%+ of revenue and we're late in a defense budget upcycle; if MRO and OE demand normalizes in 2027-28, organic growth could drop to 3-4% and the multiple compresses to 25x FCF, taking the stock to $190. Insider activity is neutral-to-slightly-negative (mostly F-InKind tax withholdings and a J-Other 39,954 share transaction that's worth understanding — likely a trust/gift, not a signal, but unexplained). The current ratio at 1.06 is tight for an industrial and worth watching if working capital swings. The other real risk: M&A is 40%+ of AMETEK's historical growth algorithm, and private-market multiples for niche industrials have compressed enough that either they overpay (ROIC declines) or they can't deploy capital (growth decelerates). Either outcome breaks the compounder narrative.
Net: I dissent from the synthesis's -35% overvalued verdict but agree with market-forces that this is fairly-to-slightly-richly valued with limited margin of safety. A defensible fair value using 28-30x FCF on $1.75B forward FCF is $220-235; current $255 is ~10% above that, not 35%. This is a "hold quality, don't chase" setup — I wouldn't initiate here but I'd own it through a 15% drawdown to $215. The synthesis DCF appears to be undershooting by using overly conservative terminal assumptions on a business that has demonstrably compounded FCF for three decades. The narrative model's framing is fair but its quantification (35-40% narrative premium) is too aggressive for a business with this durability of returns. Watch aerospace book-to-bill and organic growth ex-M&A in the next two prints — if organic slips below 4%, the thesis cracks and $200 becomes the anchor.
GPT Reading
AMEK looks exactly like the kind of business the market loves to overpay for: a highly reliable industrial compounder with excellent margins, low capital intensity, and enough acquisition credibility that investors stop demanding a margin of safety. The raw numbers absolutely support “excellent business.” Revenue went from $6.15B in 2022 to $7.40B in 2025, a solid 6.3% annualized climb, while operating income rose from $1.50B to $1.91B and net income from $1.16B to $1.48B. That is not financial engineering masquerading as growth; operating margin expanded from 24.4% to 25.8% and net margin sits at a striking 20.0% for an industrial company. Free cash flow of $1.67B on $1.48B of net income is clean conversion, and capex of just $130M on $7.40B of revenue underscores how asset-light this model has become. Balance sheet risk is modest too: $2.28B of debt against $458M cash and $10.63B equity is conservative for a company with this earnings stability.
The issue is price, not quality. At $254.79, the stock is valued at about 39.8x earnings, 8.0x sales, and 25.8x EV/EBITDA. Those are software-like or elite medtech-like multiples being assigned to a business whose actual growth profile is mid-single digits. The quarterly trend is healthy but not explosive: revenue rose from $1.78B in 2025 Q2 to $2.04B in 2026 Q2, while net income went from $358M to $407M. That is good execution, but it is still roughly 6.6% top-line growth and 7.6% earnings growth, not a reacceleration into the teens. If I annualize the first half of 2026, AME is running near $7.95B of revenue and about $1.61B of net income. The market cap of $58.4B therefore implies roughly 36x a fairly optimistic current-year earnings run-rate and more than 7x forward sales. For a business with ROIC of 12.6% and FCF growth of just 2.2% over the cited period, that is too rich. This valuation assumes that every traditional strength of the company—pricing power, aerospace exposure, M&A discipline, margin resilience—continues nearly uninterrupted.
The strongest pushback is obvious and serious: premium businesses often deserve premium multiples, and AME has earned investor trust. A gross margin of 36.0%, operating margin of 25.8%, ROE near 14%, and FCF conversion above 100% of net income are unusual in industrials. The quarterly figures also show no obvious deterioration; in fact, revenue has stepped up from $1.71B in 2024 Q3 to $2.04B in 2026 Q2, while net margins mostly held around 20% despite growth and integration activity. Debt is low enough that the company retains dry powder for acquisitions, and the tiny dividend payout ratio of 19.3% means capital can keep being recycled into deals or buybacks. If management can keep stacking 5-7% organic and bolt-on growth with modest margin uplift, then a stock that looks optically expensive can still compound acceptably from here. I just think that argument works better at 28-32x earnings than at essentially 40x.
What makes me lean against the bull case is that the underlying data do not show hidden acceleration powerful enough to justify such a stretched premium. This is not a company moving from 6% growth to 12% growth, or from 20% FCF margins to 25%; it is already highly optimized. Annual revenue added $460M in 2025 after adding $340M in 2024, so there is some improvement, but not enough to support a valuation that has detached this far from normal industrial compounding math. The insider tape is also not giving a bullish tell; it is mostly awards, option-related transactions, and small sales rather than meaningful open-market buying at these levels. I don’t see a short, because the business quality is real and downturn resistance is better than most peers, but I do see a stock priced for near-perfection.
I would change my mind if AME starts to earn its multiple through clear acceleration: think sustained 10%+ revenue growth, operating margin pushing toward 27-28%, and annual free cash flow moving above $2.0B without leverage materially rising. A large acquisition that is obviously accretive and preserves returns could also justify paying up, as could evidence that 2026 EPS power is closer to $7.50-$8.00 than the current run-rate implies. On the other hand, even one or two quarters of revenue growth slipping back to 3-4% while margins merely hold, not expand, would make the current valuation look even less defensible.
Grok Reading
Ametek’s numbers describe a high-quality industrial compounder executing exactly as advertised—and getting paid a price that assumes almost nothing can go wrong. Annual revenue climbed from $6.15B in 2022 to $7.40B in 2025, a tidy mid-single-digit path that matches the 5.9% revenue CAGR and 6.2% earnings CAGR the models flag. Net margins have locked in near 20% across the last eight quarters (19.6–22%), operating margin sits at 25.8%, and free cash flow of $1.67B on only $130M of capex underscores genuine cash conversion. Balance-sheet leverage is light (debt/equity 0.21, $2.28B debt against $10.63B equity), ROIC is a respectable 12.6%, and the recent quarterly run-rate—$2.04B revenue and $407M net income in the June 2026 quarter—shows the machine is still humming. None of that is in dispute. What stands out is the multiple attached to it: 39.8× earnings, 25.8× EV/EBITDA, 8.0× sales, and a free-cash-flow yield of roughly 2.9% at a $58.4B enterprise. With organic-plus-M&A growth stuck in the mid-single digits and FCF CAGR a sluggish 2.2%, the market is capitalizing a 6% grower at nearly 40× as if margin expansion and flawless bolt-on integration are perpetual free options.
The valuation synthesis that marks the name ~35% above a $166 signal-adjusted fair value is directionally correct; the raw data simply do not support a 40× multiple once you strip out the “best-in-class roll-up” narrative. Recent revenue year-over-year of 6.6% and earnings growth of 7.6% are solid but decelerating on a sequential quarterly basis, and the secondary signals already register macro headwinds plus a decelerating revenue trend. Insider activity is noise—mostly option exercises, tax withholds, and awards—offering no signal either way. At current levels the stock embeds the entire 30-year compounding track record as a permanent valuation premium rather than as a reason to pay a modest premium and still demand a margin of safety.
The strongest counter-argument is that Ametek has earned the right to trade rich. Gross margins have held 36%, operating margins expanded steadily from the early-2020s base, and management has repeatedly turned fragmented niche acquisitions into higher-return assets inside aerospace test, power systems, and precision instrumentation. A patient holder who bought the quality and ignored the multiple has been rewarded for decades; the narrative layer correctly notes low cult coefficient and durable institutional sponsorship. If you believe ROIC stays north of 12–13%, organic growth never slips below mid-single digits, and the M&A pipeline continues to deliver 100–200 bp of incremental growth without multiple compression, then 25–26× EBITDA is simply the clearing price for scarce industrial compounders and the DCF understates franchise value. I weigh that history, but I do not let it override arithmetic: a 2.9% FCF yield and 6% growth leave almost no cushion if aerospace/defense (a material slice of the book) softens or if integration returns fade.
I would flip to neutral or constructive only if the next two to three quarters deliver sustained double-digit organic revenue growth (not just acquisition-inflated totals), operating margin expands another 100–150 bp toward the high-20s, or the multiple compresses toward the mid-20s P/E / ~18–20× EV/EBITDA while FCF continues to compound above 8%. Absent those, the stock remains a fine business priced for perfection.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Ametek shows the profile of a well-run mature industrial: revenue expanded from $6.15B (2022) to $7.40B (2025), a ~6% CAGR, with gross margins holding 35-36% and operating margins steady at 24-26%. Net income grew from $1.16B to $1.48B and FCF ran $1.6-1.7B in each of the last three years, comfortably exceeding net income (OCF/NI 1.21x, accruals -1.9% of assets). Beneish M at -2.43 and Altman Z at 8.38 both sit in clean/safe territory, and no mechanical earnings-quality flags trip. Diluted share count is essentially flat (231-232M, -0.2% CAGR) with buybacks running 4.3x SBC and SBC only 0.7% of revenue - per-share value is being protected rather than eroded. Balance sheet is the one soft spot: net debt of ~$1.83B against just $458M liquid cash, and short-term debt of $1.21B exceeds cash on hand. Given $1.67B annual FCF, this is a working-capital/refi issue rather than a solvency concern, but it means the balance sheet is a constraint, not a cushion. Insider tape is neutral-to-slightly-negative: no open-market buys in 12 months, one small S-sale ($115K by Amato), rest are routine F-InKind tax withholdings and option exercises - no directional signal either way.
Verify before trusting this (5)
- Debt maturity ladder and refinancing terms for the $1.21B short-term debt
- Organic vs acquisition split of revenue growth (Ametek is an active acquirer - is the compounding organic or bolt-on driven?)
- Segment concentration and end-market exposure (aerospace, medical, process)
- Goodwill and intangibles as % of assets given M&A cadence, and any impairment history
- Cash conversion cycle trend and whether working capital is masking any deterioration
The e2e composite fair value of $141.09 and signal-adjusted $165.72 both imply 35-45% downside from $254.79. The DCF ($125.95) and EPV floor ($64.35) are punitive and probably understate a genuine mid-20s-margin compounder with >100% cash conversion, but the anchored-PE of $248.12 is the only method that even approaches the current price - and it lands slightly below it. That means the single method most favorable to a high-quality industrial still says fairly-valued at best, while every cash-flow-based method screams rich. Triangulating, a fair deserved value for a strong-but-levered specialty industrial with the quality lens's 72 score is somewhere in the $200-230 zone - clearly below $254.79. What is priced in: continued mid-single-digit organic growth, sustained mid-20s margins, uninterrupted accretive M&A, and no multiple compression. That is the textbook 'priced for perfection' setup the bear narrative flags. There is no margin of safety here; you are paying full freight for a proven compounder and relying entirely on continued execution plus a stable multiple to earn a return. Earnings quality is high (score 3), so no haircut is warranted, but high quality does not manufacture cheapness - it justifies a premium multiple, which the market has already awarded and then some.
Verify before trusting this (4)
- Organic growth guidance vs the mid-single-digit assumption baked into the anchored-PE
- M&A pipeline and deployed-capital returns - the compounder story requires continued accretive deals
- Aerospace and defense backlog trends given bear-case budget uncertainty
- Whether the $1.21B short-term debt gets refinanced at materially higher rates and hits EPS
The tape is mildly risk-on with VIX at 14.3 and the S&P near highs, which is a benign setting for a beta-1.0 quality industrial like AME. The active narrative is a low-drama 'best-in-class serial acquirer / steady-compounder' story - moderate intensity but durable, with low cult risk - and the news flow of the last week actively reinforces it: a Q2 beat, raised guidance, dividend declared, analysts described as moderately bullish. That is the archetype of gentle, persistent buying pressure rather than momentum-chasing.
Verify before trusting this (4)
- Any downtick in semi/aerospace/MedTech end-market commentary from peers that could crack the broad-based demand story
- Sell-side target revisions in the coming weeks - a wave of upward revisions would strengthen the tailwind
- 10y yield moving above 4.75% which would pressure premium-multiple compounders more visibly
- Whether the post-earnings drift holds or fades - a stall would signal narrative fatigue at these levels
AI reaches AMETEK through three narrow channels rather than the core: it can automate the analysis and interface layer sitting atop instruments, which is a modest pricing risk on the software-differentiated end of Electronic Instruments; it lowers the engineering and SG&A cost of running ~30-plus decentralized niche businesses, which in a 36% gross margin / 25.8% operating margin structure with $1.67B FCF converts into incremental margin and faster acquisition integration; and it raises demand for the physical enablers of compute — thermal management, interconnects, motion and test equipment for semiconductor and power electronics. The customer need (measure, move, cool, connect with certified precision) is physics, not cognition, so the solution persists; the monetized unit is a shipped device, not a seat or a billable hour, which insulates revenue from the seat-compression dynamic hitting software and services. The main way this goes wrong is competitive: cheap AI-assisted design plus commodity compute lets focused entrants replicate mid-tier instrument functionality, compressing the niche pricing power that justifies AMETEK's premium roll-up economics.
None surfaced.
Verify before trusting this (8)
- Aerospace and defense order backlog
- Semiconductor equipment capex cycle
- Medical OEM component demand
- Thermal management order growth
- Specialty metals utilization
- Design-win announcements in power electronics
- Software attach and license revenue mix
- Instrument ASP trends by line
The world Ametek sells into is neither inflecting up nor breaking down: a steady-phase industrial capital-goods cycle with a mature 3.6% underlying growth rate, financed against a 4.63% long rate that makes customers slower to approve projects. Nothing in the macro set-up creates a new demand wave; nothing threatens the installed base of spec'd-in instruments either. Structural tailwinds are narrow and real — electrification and power-electronics test, aerospace build rates and defense electronics content, medical diagnostics throughput — and Ametek's content sits in exactly those niches at small dollar values inside large customer programs, which is what protects pricing. The offsetting truth is that this is a portfolio assembled to be steady, not to be fast: no single end market is large enough to bend the consolidated growth rate, so the company's trajectory is essentially the weighted average of a flat world plus whatever the M&A pipeline adds. That yields a durable but bounded mid-single-digit revenue path with high-single-digit earnings growth — the shape a diversified niche instrumentation compounder should produce in a steady-demand decade.
When we made this prediction on Aug 15, 2026, AME was $254.79. We expect it to be $238.00 by Feb 2027, and we consider it great value under $205.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 15, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.